The Demand for Cost-Effective Solutions to Treat Obesity Could Prove to be an Opportunity for Bovine Serum Albumin (BSA) Market
The global bovine serum albumin market is estimated to be valued at USD 255 million in 2019 and is projected to reach USD 304 million by 2025, recording a CAGR of 3.0%. Due to the growing livestock population and the subsequent increase in demand for blood-derived products, the market for bovine serum albumin is growing.
By form, the global bovine serum albumin market is segmented into dry and liquid forms. The demand for the dry form of BSA is high due to benefits offered, such as long shelf-life, stability, ease of handling, and transportation. In most instances, the end-users prefer using the dry form since it is easier to dilute as well.
The technical-& diagnostic-grade of BSA is the most extensively used grade due to its characteristic features such as solubility properties and ease of filtration. Its cost-effective nature has also made it a preferred option as a protein standard in the diagnostic industry. Some of the commonly used grades of BSA are the standard grade, protease-free, low endotoxin grade, protease- and DNase-free grade, biotinylated BSA grade, and microbiological grade. The low endotoxin grade of BSA is specifically manufactured to meet the requirements of bacterial and mammalian cell culture applications.
Major players such as Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc (US), Merck KGAA (Germany), Itoham Yonekyu Holdings Inc (Japan), Proliant Biologicals (US), Kraeber & Co Gmbh (Germany), Rockland Immunochemicals Inc (US), Rocky mountain biologicals (US), BelHealth investment partners, LLC (US), Bio-Techne Corporation (US), Prospec-Tany Technogene Ltd (Israel), and LGC Group (UK), (Singapore) in the bovine serum albumin market are focusing on new product launches, expansions & investments, and mergers & acquisitions, to expand their global footprint.
Comments
Post a Comment